NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Supreme Court Of India
    Central Bureau Of Investigation (CBI)
    Indian Army
    Indian Railways
    Indian Air Force
    NewsBytes
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / India News / New anti-COVID drug may cost up to Rs. 3,000: Report
    India

    New anti-COVID drug may cost up to Rs. 3,000: Report

    New anti-COVID drug may cost up to Rs. 3,000: Report
    Written by Saptak Datta
    Dec 30, 2021, 03:52 pm 2 min read
    New anti-COVID drug may cost up to Rs. 3,000: Report
    Molnupiravir was recently granted emergency use authorization (EUA) by the Drugs Controller General of India (DCGI).

    Molnupiravir, an antiviral medication, is projected to cost between Rs. 2,000 and Rs. 3,000 for a full treatment. The drug—created by Merck and Ridgeback-Biotherapeutics—was recently granted emergency use authorization by the Drugs Controller General of India (DCGI) for use among COVID-19 patients. Merck said earlier it plans to utilize a graded pricing structure based on the World Bank income criteria.

    Why does it matter?

    • Molnupiravir is the first oral antiviral treatment for COVID-19 to be approved.
    • Merck says the drug cuts hospitalizations and deaths by half in patients with early COVID-19 symptoms.
    • The development takes precedence with the emergence of the highly contagious Omicron variant of coronavirus.
    • Amid concerns of a third wave of COVID-19, experts predict coronavirus infections in India may rise soon.

    Which Indian companies will be manufacturing the drug?

    Molnupiravir will be manufactured by 13 Indian pharmaceutical companies, including Cipla, Torrent, Dr. Reddy's, Sun Pharma, Mylan, Natco, Hetero, and Optimus. "Stocks of molnupiravir are expected to reach us by January 3," Arihant Chemist Managing Director Rajesh Jain told The Economic Times.

    Who will be eligible for molnupiravir?

    Molnupiravir is not recommended for children under the age of 18. The medication is also not meant for COVID-19-infected individuals who need to be hospitalized immediately. It only helps prevent COVID-19 from progressing into severe disease in those with early symptoms. An 800 mg dose twice a day is recommended. It is not permitted to be consumed for more than five consecutive days.

    Molnupiravir to undergo further testing

    The 13 companies will test molnupiravir on 1,000 patients each to determine its safety as part of post-marketing surveillance (PMS), CNN-News18 reported. The DCGI reportedly expects the trial's data within three months. The companies will be required to submit data on the drug's effects and side-effects every three months. The latest data on patients being administered molnupiravir will also be shared with the companies.

    How does molnupiravir work?

    Molnupiravir works by causing errors in the virus's reproduction mechanism, according to the UK drug regulatory agency. The treatment causes mutations to accumulate by deceiving the virus into incorporating its material into copies of viral RNA. This renders the virus unable to replicate. The medication is able to lessen the severity of the condition by keeping virus rates low in the body.

    Share this timeline
    Facebook
    Whatsapp
    Twitter
    Linkedin
    Latest
    World Bank
    Drugs Controller General of India
    COVID-19
    Omicron variant

    Latest

    POCO X5 Pro 5G launched in India at Rs. 23,000 Poco
    Tagenarine Chanderpaul slams a record-breaking double-century: Key stats West Indies Cricket Team
    Audi Q3 Sportback bookings open: Check alternative SUVs before ordering Audi
    'Salaam Venky': Kajol's emotionally-charged film gets an OTT release date!  ZEE5

    World Bank

    India questions World Bank's stand on Indus Waters Treaty India
    India wants to change Indus Waters Treaty, cites Pakistan's 'intransigence' India
    India's economy 'resilient,' to grow 6.9% in FY23: World Bank Gross Domestic Product
    Pakistan's finance minister quits, tainted PML-N leader to replace him Pakistan

    Drugs Controller General of India

    Serum Institute seeks DCGI's approval for Covovax as booster dose Serum Institute of India
    Lumpy skin disease kills 67,000 cattle across India: Details here Narendra Modi
    Clinical trials for nasal COVID-19 vaccine complete: Bharat Biotech Paris
    DCGI clears COVAXIN, Corbevax for children aged 6-12, 5-12 years COVID-19 Vaccine

    COVID-19

    US to ease visa backlog for Indians, opens overseas embassies H-1B Visa
    Kerala: Man gets 3 life-terms for raping, impregnating minor daughter Kerala
    Amid global slowdown predictions, IMF calls India 'bright spot' International Monetary Fund
    India's 1st nasal COVID-19 vaccine by Bharat Biotech launched Vaccine

    Omicron variant

    Omicron subvariant XBB.1.5: What do we know so far COVID-19
    COVID-19: WHO urges travelers to mask up amid XBB.1.5 spread World Health Organization
    China slams 'distorted' Western reports on COVID-19 response, eases restrictions China
    COVID-19: Mock drills across India to test preparedness; more updates COVID-19

    Love India News?

    Subscribe to stay updated.

    India Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023